The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Share News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Mereo BioPharma Could Net USD300 Million From Navicixizumab Deal

Mon, 13th Jan 2020 12:24

(Alliance News) - Mereo BioPharma Group PLC shares surged on Monday, after the company sealed a development & commercialisation licensing agreement with Massachusetts-based Oncologie Inc for the navicixizumab ovarian cancer treatment drug.

Shares in the company climbed 33% to 43.75p in London on Monday.

As part of the agreement, Mereo will receive USD4 million upfront, and in exchange, Oncologie will receive an exclusive worldwide license to develop and commercialise navicixizumab. London-based Mereo could receive another USD2 million, subject to the passing of chemistry, manufacturing & controls milestones, the biopharmaceutical firm said.

What's more, Mereo could be entitled to a further USD300 million related to commercial milestones.

Mereo said: "Oncologie will be responsible for all future research, development and commercialization of navicixizumab. Additionally, Mereo will be eligible to receive up to USD300 million in future clinical, regulatory and commercial milestones, tiered royalties ranging from the mid-single-digit to sub-teen percentages on global annual net sales of navicixizumab, as well as a negotiated percentage of sublicensing revenues from certain sublicensees."

In October, navicixizumab was given fast track designation in the US by the Food & Drug Administration as a treatment for heavily pretreated ovarian cancer.

Mereo acquired navicixizumab in its April merger with OncoMed Pharmaceuticals Inc.

"We believe Oncologie is expertly positioned to further advance navicixizumab through clinical development and towards potential commercialisation.

"While we believe navicixizumab is an exciting oncology asset, we continue to focus our primary efforts on the development of our innovative rare disease portfolio including our lead product candidate setrusumab for the treatment of osteogenesis imperfecta, which continues to advance towards a pivotal phase 3 pediatric study."

In November, Mereo unveiled promising results from a study on setrusumab, a drug for the treatment of bone disease osteogenesis imperfecta. The study met both its primary and secondary endpoints.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Sep 2019 11:53

Mereo BioPharma Loss Narrows On Gain From OncoMed Buy And Expenses

(Alliance News) - Mereo BioPharma Group PLC on Tuesday posted a slightly narrowed loss for the first half of 2019 on a gain from its OncoMed Pharmaceuticals Inc acquisition, as well as lower in at

Read more
16 Aug 2019 15:32

DIRECTOR DEALINGS: Mereo BioPharma Trio Of Directors Acquire Shares

(Alliance News) - Mereo BioPharma Group PLC on Friday said General Counsel Charles Sermon, Chief Executive Officer Denise Scots-Knight and Head of Corporate Development John Richard, all purchased

Read more
16 Jul 2019 14:46

Mereo BioPharma Names Richard Francis As New Pharmaceutical Head

(Alliance News) - Mereo BioPharma has appointed Richard Francis as the new head of pharmaceutical development, effective August 1, the biopharmaceutical company said on Tuesday.Francis was

Read more
12 Jun 2019 16:04

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 JuneTescoWM Morrison SupermarketsSirius MineralsJust Jack 14 Evans 17 18

Read more
30 May 2019 10:52

Mereo BioPharma Reports Positive Data For Anti-Sclerostin Antibody

LONDON (Alliance News) - Mereo BioPharma Group PLC on Thursday reported positive six-month data for its anti-sclerostin antibody, BPS-804, in the treatment of adult patients with osteogenesis were

Read more
30 May 2019 10:40

Mereo BioPharma releases 'encouraging' data from setrusumab study

(Sharecast News) - Clinical stage biopharmaceutical company Mereo BioPharma Group announced encouraging six-month data from the open label arm of its phase 2b dose-ranging clinical study in adults with type I, III or IV osteogenesis imperfecta (OI) treated with BPS-804 ('setrusumab'), or the 'ASTEROID' study, on Thursday.

Read more
23 May 2019 17:58

DIRECTOR DEALINGS: Mereo Biopharma Non-Executive Bains Buys Shares

LONDON (Alliance News) - Mereo Biopharma PLC said Thursday that Non-Executive Director Peter Bains purchased around GBP42,750 in stock in a deal on Tuesday.Bains bought 47,500 shares at a

Read more
29 Apr 2019 12:05

Mereo BioPharma Set For Transformational 2019 As Loss Narrows Sharply

LONDON (Alliance News) - Mereo BioPharma Group PLC on Monday said its loss narrowed in 2018 following the completion of several product trials.The clinical stage biopharmaceutical company a

Read more
23 Apr 2019 14:48

Mereo BioPharma Completes Merger With OncoMed Pharmaceuticals

LONDON (Alliance News) - Mereo BioPharma Group PLC on Tuesday said its all-stock merger with OncoMed Pharmaceuticals Inc is now complete.OncoMed's shareholders approved the deal on last

Read more
18 Apr 2019 11:37

OncoMed Shareholders Approve All-Share Merger With Mereo BioPharma

LONDON (Alliance News) - Mereo BioPharma Group PLC on Thursday said OncoMed Pharmaceuticals Inc shareholders have approved the merger of the two companies.Mereo BioPharma, a clinical stage

Read more
15 Apr 2019 10:07

Mereo Agrees With US FDA On Phase Three Trial Design For Acumapimod

LONDON (Alliance News) - Mereo BioPharma Group PLC said on Monday it has concluded an end of Phase Two meeting with the US Food & Drug Administration regarding acumapimod as a treatment for of

Read more
15 Mar 2019 16:57

Mereo BioPharma Scures Further Acceptances From OncoMed Shareholders

LONDON (Alliance News) - Mereo BioPharma Group PLC on Friday said it has now received support agreements in respect of 21.1% of OncoMed Pharmaceuticals Inc's shares and expects to complete the

Read more
15 Mar 2019 15:16

Mereo BioPharma merger with OncoMed moves closer

(Sharecast News) - Clinical-stage biopharmaceutical company Mereo BioPharma Group updated the market on its proposed combination with OncoMed Pharmaceuticals on Friday, which it said should close in the second quarter of 2019.

Read more
22 Feb 2019 14:35

Mereo BioPharma Withdraws US Listing Application On OncoMed Deal (ALLIPO)

LONDON (Alliance News) - Mereo BioPharma Group PLC said Friday it has requested the withdrawal of its US IPO application as it continues to work on its business combination with US pharmaceutical

Read more
11 Feb 2019 12:44

Mereo BioPharma Founding Director Departs Before OncoMed Combination

LONDON (Alliance News) - Mereo BioPharma Group PLC on Monday announced the immediate departure of founding board director Frank Armstrong prior to Mereo's combination with US firm OncoMed was

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.